Navigation Links
Corgenix Receives Third U.S. Patent on AtherOx(R) Technology
Date:9/25/2008

mpson, President and CEO of Corgenix said, "We are very pleased to announce this important addition to our IP portfolio. We have one product already cleared by the FDA and several products in the later stages of the development pipeline with FDA submission expected in the next year or so. Since cardiovascular disease is one of the world's leading causes of death, the early detection of atherosclerosis has become increasingly important, and we are optimistic about our ability to serve this significant market."

In all countries where the use of products employing this technology have not been cleared, the products shall not be used for diagnostic use as the performance characteristics have not been established.

About AtherOx(R)

The AtherOx(R) technology utilizes oxidized low-density-lipoprotein (oxLDL) complexed with the plasma protein B2GPI. Although oxLDL has been implicated in cardiovascular disease, according to results published in the Annals of N.Y. Academy of Science (2007), determination of oxLDL/.2GPI complexes, rather than oxLDL alone, may be a more physiologic and accurate way of assessing the risk of progressive atherosclerotic cardiovascular disease in individuals with systemic lupus erythematosus and lupus-like disorders. Corgenix licensed this technology in 2002, and is developing additional products utilizing this unique platform. In addition to the three U.S. patents which have been issued, several others are pending.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for vascular diseases, immunology disorders, and bone and joint disorders, including the world's only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 52 diagnostic products through a global distribution network. More information is available at

SOURCE Corgenix Medical Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Corgenix Signs Technology Licensing Agreement With Japanese Government
2. Corgenix to Exhibit AspirinWorks(R) Test at ACC 2008 Meeting in Chicago
3. Corgenix Announces FDA Clearance for IgG Anti-AtherOx(R) Test Kit
4. Corgenix to Host Conference Call to Discuss Third Quarter Fiscal 2008 Results
5. Corgenix to Exhibit AspirinWorks(R) Test at ADA 2008 Meeting in San Francisco
6. Corgenix Expands Scientific Advisory Board
7. Corgenix to Host Conference Call to Discuss Fiscal 2008 Results
8. Corgenix Reports Fiscal 2008 Financial Results
9. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
10. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
11. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2015)... Join us for a webinar at 12 pm ... using the Transcreener® ADP Assay , Register Now ... being incorporated into lead development efforts because longer engagement ... therapeutic window and reduced side effects. Though residence ... surface plasmon resonance, conjugation of drugs can affect their ...
(Date:4/24/2015)... , April 24, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... MaterialScience as the supplier of bio-succinic acid used ... polyurethanes for textile applications that Bayer MaterialScience has ... launched IMPRANIL ® eco, a series of ... reaches as high as 65%.  IMPRANIL ® ...
(Date:4/24/2015)... 24, 2015 Seoul Semiconductor announced ... various applications in the lighting market. In ... of this technology in emerging markets such as ... wide range of applications such as streetlight and ... lighting. , First launched in 2005 the Acrich ...
(Date:4/23/2015)... , April 23, 2015 BioTE Medical President ... book "Age Healthier Live Happier - Avoiding Over-Medication through ... Age Management Medicine Group Conference at JW Marriott / ... ",Age Healthier Live Happier, is a welcomed ... over-medication and searching for a higher quality of life ...
Breaking Biology Technology:BellBrook Labs Webinar: Analyzing Kinase Inhibitor Residence Times using the Transcreener® ADP Assay 2Bayer MaterialScience Names BioAmber As Its Supplier For New Product Line - Bio-succinic acid forms backbone of innovative new bio-based polyurethanes for textiles 2Bayer MaterialScience Names BioAmber As Its Supplier For New Product Line - Bio-succinic acid forms backbone of innovative new bio-based polyurethanes for textiles 3Bayer MaterialScience Names BioAmber As Its Supplier For New Product Line - Bio-succinic acid forms backbone of innovative new bio-based polyurethanes for textiles 4Acrich Technology from Seoul Semiconductor Adopted in Installations Worldwide 2Release and Book Signing of BioTE Medical President Gary Donovitz M.D. 'Age Healthier Live Happier' at Age Management Medicine Group (AMMG) Conference 2Release and Book Signing of BioTE Medical President Gary Donovitz M.D. 'Age Healthier Live Happier' at Age Management Medicine Group (AMMG) Conference 3
... Cylene Pharmaceuticals today announced,the initiation of a Phase ... carcinoid/neuroendocrine tumors (C/NET), which are malignant,cancers arising from ... "Quarfloxin (CX-3543) is a small molecule ... abnormal nucleoli of cancer cells, thereby,selectively inducing apoptotic ...
... PAREXEL International,Corporation (Nasdaq: PRXL ), ... the Company has been named the "Best Contract,Research ... award was,presented to PAREXEL at the fourth annual ... London, England. The Scrip Awards are designed to,celebrate ...
... Precision(R), Inc. a,leading provider of imaging, measurement, and ... that it will introduce a new imaging,system at ... conference with,twice the resolution of traditional microscopes. ... system developed by scientists at the, University of ...
Cached Biology Technology:Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors 2Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors 3PAREXEL Receives Best CRO Award from Scrip 2PAREXEL Receives Best CRO Award from Scrip 3PAREXEL Receives Best CRO Award from Scrip 4Applied Precision Introduces New Super-Resolution Imaging System Doubling Resolution of Traditional Microscopes 2
(Date:3/31/2015)... 2015   Guidepoint , a leading global research ... Pain Management TRACKER, part of the Guidepoint TRACKER ... the medical device and therapeutics markets. The Post-Surgical Pain ... volumes, market share, and adoption rates across three major ... surgery. The Post-Surgical Pain Management TRACKER will ...
(Date:3/26/2015)... 2015 The Granite Club, ... athletic club, today announced it has implemented a state-of-the-art ... movement for members and staff, while restricting access to ... we selected FST,s IMID Access system because it has ... members and staff, in addition to unparalleled security," said ...
(Date:3/24/2015)... Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced the addition of ... report to their offering. This report analyzes the ... the following Segments: Face Biometrics, and Voice Biometrics. The report provides ... Japan , Europe , ... Africa , and Latin America ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6
... Research Institute (NHGRI), one of the National Institutes ... Sequencing Research Network will begin sequencing 12 more ... and several important insects, as part of its ... genome. , The National Advisory Council for Human ...
... a marvel of versatility, creating a variety of cells that ... out these tasks, immune cells follow a career path that ... in the May 2005 issue of Immunity, Fox Chase Cancer ... Dietmar J. Kappes, Ph.D., show that cell-receptor signaling strength influences ...
... the biological literature resides in full text articles, instead ... publicly available literature data mining tools. Most literature mining ... extracted from curated gene or protein databases. This is ... the many name variants which are used to refer ...
Cached Biology News:NHGRI targets 12 more organisms for genome sequencing 2NHGRI targets 12 more organisms for genome sequencing 3NHGRI targets 12 more organisms for genome sequencing 4NHGRI targets 12 more organisms for genome sequencing 5Fox Chase study shows that weakened T-cell receptor signals change T-cell lineage 2Fox Chase study shows that weakened T-cell receptor signals change T-cell lineage 3
Tan solid. A glycoside used to permeabilize cellular membranes. Exhibits hemolytic activity. Contaminants: ash: ≤10%. Soluble in H 2 O. pH 4.4 - 4.6. RTECS VQ1400000, CAS 8047-15-2. References:...
Anti Autotaxin /ENPP2 , - (Rabbit)...
... yellow solid. An N-nitroso-containing diabetogenic compound ... donor in pancreatic islets. An antibiotic ... alkylation and DNA strand breaks in ... HPLC. Soluble in H 2 O. ...
Mouse monoclonal antibody to CDC2L5 - cell division cycle 2-like 5 (cholinesterase-related cell division controller)...
Biology Products: